TECHNOLOGY LICENSING OPPORTUNITY: Plane-Wave Ultrasound Tomography for Cancer Imaging
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Los Alamos National Laboratory (LANL) is offering a Technology Licensing Opportunity for its Plane-Wave Ultrasound Tomography platform, designed for advanced cancer imaging, particularly for prostate and breast cancer. This is an invitation for companies to license the technology for commercialization, not a call for external services. Responses are due by June 1, 2026.
Technology Overview
LANL's Plane-Wave Ultrasound Tomography is a next-generation imaging platform that improves how tissue properties are reconstructed from ultrasound data. It addresses limitations of current clinical ultrasound by providing more accurate, higher-quality, and quantitative imaging for better cancer detection and characterization. The technology includes ultrasound waveform tomography/inversion, efficiency improvements, and super-resolution imaging methods.
Key Advantages
- Better tissue characterization than standard ultrasound
- Can use transmission data, reflection data, or both
- Supports prostate cancer and breast cancer applications, among other diseases
- Aims to improve image quality and resolution while providing additional tissue-property information
- Helps with screening, diagnosis, and treatment monitoring
- Includes related methods that improve reconstruction stability and efficiency
Market Applications
- Medical and Diagnostic Imaging (ultrasound systems, tissue characterization)
- Cancer Screening (prostate and breast cancer detection programs)
- Treatment Monitoring (tracking response during therapy)
- Women's Health (breast imaging and follow-up evaluation)
- Urology (prostate imaging and assessment)
Licensing Details
LANL's licensing program focuses on moving inventions to commercial innovations. Patented and patent-pending inventions are available through exclusive and non-exclusive licensing agreements. The technology has a Technology Readiness Level (TRL) of 5 and is supported by multiple U.S. Patents. This opportunity is managed by the Department of Energy (DOE), specifically the TRIAD - DOE CONTRACTOR office.
Response & Contact
Interested parties should contact licensing@lanl.gov for specific discussions regarding licensing agreements. The deadline for expressing interest is June 1, 2026, at 11:00 PM Z. This notice was published on May 11, 2026.